Direct oral anticoagulant use and risk of severe COVID-19.

Flam B, Wintzell V, Ludvigsson JF, MÃ¥rtensson J, Pasternak B

J Intern Med - (-) - [2020-12-01; online 2020-12-01]

Hypercoagulability and thromboembolism are prominent features of severe COVID-19, and ongoing anticoagulant use might be protective. We conducted a nationwide register-based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (DOAC) use was associated with reduced risk of hospital admission for laboratory-confirmed COVID-19, or a composite of intensive care unit (ICU) admission or death due to laboratory-confirmed COVID-19. DOAC use (n=103 703) was not associated with reduced risk of hospital admission for COVID-19 (adjusted hazard ratio [aHR] [95% confidence interval] 1.00 [0.75-1.33] vs. non-use atrial fibrillation comparator [n=36 875]; and aHR 0.94 [0.80-1.10] vs. non-use cardiovascular disease comparator [n=355 699]), or ICU admission or death due to COVID-19 (aHRs 0.76 [0.51-1.12], and 0.90 [0.71-1.15], respectively). Ongoing DOAC use was not associated with reduced risk of severe COVID-19, indicating that prognosis would not be modified by early outpatient DOAC initiation.

Category: Health

Funder: VR

Type: Journal article

PubMed 33258156

DOI 10.1111/joim.13205

Crossref 10.1111/joim.13205


Publications 7.1.2